Wells Fargo & Company MN raised its position in shares of Alexion Pharmaceuticals (NASDAQ:ALXN) by 7.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,307,717 shares of the biopharmaceutical company’s stock after buying an additional 95,794 shares during the quarter. Wells Fargo & Company MN owned about 0.59% of Alexion Pharmaceuticals worth $145,759,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Delpha Capital Management LLC purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at approximately $102,000. CNB Bank purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at approximately $150,000. Lourd Capital LLC purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at approximately $221,000. CIBC World Markets Inc. purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at approximately $263,000. Finally, Bailard Inc. purchased a new position in Alexion Pharmaceuticals during the 4th quarter valued at approximately $263,000. Institutional investors and hedge funds own 92.40% of the company’s stock.
Shares of ALXN stock opened at $121.07 on Monday. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86. The company has a market cap of $26.94 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 1.09 and a beta of 1.11.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.18. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The firm had revenue of $930.90 million during the quarter, compared to analyst estimates of $920.50 million. During the same period last year, the company earned $1.38 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 7.0% compared to the same quarter last year. research analysts expect that Alexion Pharmaceuticals will post 6.28 EPS for the current year.
ALXN has been the subject of a number of recent research reports. Citigroup lifted their target price on Alexion Pharmaceuticals from $170.00 to $173.00 and gave the stock a “buy” rating in a report on Monday, April 30th. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, March 17th. SunTrust Banks set a $172.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, February 12th. ValuEngine cut Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $151.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $155.50.
In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total transaction of $194,723.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Heidi L. Wagner sold 698 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total value of $83,306.30. The disclosure for this sale can be found here. Insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.